Back to Search
Start Over
A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.
- Source :
-
Medical mycology case reports [Med Mycol Case Rep] 2019 Dec 05; Vol. 27, pp. 17-21. Date of Electronic Publication: 2019 Dec 05 (Print Publication: 2020). - Publication Year :
- 2019
-
Abstract
- Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections. We present a case of CNS aspergillosis in a CLL patient on first line ibrutinib therapy. We summarize existing case reports and case series of invasive aspergillosis in patients on ibrutinib, the pathogenesis of invasive aspergillosis, and discuss the clinical controversies regarding anti-fungal prophylaxis in this population.<br />Competing Interests: JP discloses the following consulting/advisory committee/research grants: Astellas, Merck, F2G, Cidara, Pfizer, Scynexis, Viamet, Amplyx, Vical, Matinas, Minnetronix. DB discloses the following consulting/advisory committee/research grants: AbbVie, ArQule, AstraZeneca, BeiGene, DTRM, Genentech, Juno, MEI Pharma, Novartis, Pharmacyclics, Teva, TG Therapeutics, Tolero, Verastem. JM, EE, SW and JS have nothing to disclose.<br /> (© 2019 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.)
Details
- Language :
- English
- ISSN :
- 2211-7539
- Volume :
- 27
- Database :
- MEDLINE
- Journal :
- Medical mycology case reports
- Publication Type :
- Report
- Accession number :
- 31879587
- Full Text :
- https://doi.org/10.1016/j.mmcr.2019.12.007